Amgen will develop and commercialize Advaxis’ ADXS-NEO, a preclinical cancer immunotherapy candidate, through a global agreement that could generate more than $540 million for Advaxis, as reported by Genetic, Engineering & Biotechnology News.

According to the report, ADXS-NEO is designed to activate a patient's immune system to respond against the neoepitopes contained in and identified from each individual patient's tumor. The collaboration is designed to combine Amgen's development expertise in immuno-oncology with Advaxis' MINE (My Immunotherapy Neo-Epitopes) program.

The companies plan to develop patient-specific immunotherapy constructs that incorporate the neoepitope sequences identified in the patient's tumor cells. Clinical studies using ADXS-NEO are in development and expected to begin in 2017.

Read the full article